Bayer HIV Blood Product Scandal: Settlements and Prosecutions

The Bayer HIV blood product scandal refers to the mid-1980s decision by Bayer’s Cutter Biological division to keep selling unheated, HIV-risky clotting-factor concentrate to hemophilia patients in Asia and Latin America for more than a year after a safer heat-treated version was already on U.S. and European shelves. Thousands of hemophiliacs worldwide were infected with HIV through contaminated Factor VIII and Factor IX products made by Cutter and other manufacturers. The fallout produced roughly $600 million in U.S. settlements, hundreds of millions more in international compensation, and criminal convictions of pharmaceutical executives and public officials in Japan, France, Germany, and Canada.

What Cutter Did

Hemophilia patients rely on clotting-factor concentrates to control bleeding. In the early 1980s these products were made by pooling plasma from as many as 10,000 or more donors per batch, so a single infected donor could contaminate an entire production run.¹ By July 1982 the CDC had reported hemophiliacs falling ill with AIDS.² In January 1983 Cutter’s own manager of plasma procurement wrote internally that there was “strong evidence to suggest that AIDS is passed on to other people through… plasma products.”³ Months later, in June 1983, Cutter told its international distributors the link was “unsubstantiated speculations” and called the public response “irrational.”⁴

Heat treatment inactivated HIV in clotting factor. The FDA approved a heat-treated Factor VIII in March 1983, and by October 1984 a CDC study confirmed the virus was “undetectable” after treatment.³ Cutter introduced its own heat-treated product in the United States in late February 1984.

Rather than withdraw the older unheated product, Cutter kept manufacturing and exporting it. Internal documents show the reasons were financial: the company wanted to deplete existing inventory and fulfill fixed-price contracts for which the older product was cheaper to make.⁵ November 1984 meeting minutes noted “excess nonheated inventory” and a plan to “review international markets again to determine if more of this product can be sold.”³ Cutter told a Hong Kong distributor to “use up stocks” of the old medicine, and when distributors called the product “AIDS-tainted,” the company replied that it posed “no severe hazard” and was the “same fine product we have supplied for years.”⁴ In February 1985 a Cutter task force asked whether the company could “in good faith continue to ship nonheat-treated coagulation products to Japan.” The recorded answer was “yes.”

All told, Cutter shipped more than 100,000 vials of unheated concentrate, worth over $4 million, to Hong Kong, Taiwan, Malaysia, Singapore, Indonesia, Japan, and Argentina after the safer product was on the market.⁵ The shipments continued until July 1985, when the FDA ordered them stopped.³

Bayer was not alone. Baxter Healthcare, Armour Pharmaceutical, and Alpha Therapeutic were named as co-defendants in lawsuits alleging they knowingly exported contaminated Factor VIII in 1984 and 1985 after pulling the products from the U.S. and Europe.⁶

Who Was Infected

Global figures are hard to pin down because early records are incomplete and HIV testing did not exist for much of the exposure window. Reported totals include:

United States: an estimated 8,000 to 10,000 hemophiliacs infected in the late 1970s and early 1980s; by late 1994 roughly 3,000 had died, at a rate then described as “one per day.”⁷
Japan: approximately 1,800 hemophiliacs infected, about 500 dead.⁸
Hong Kong and Taiwan: more than 100 hemophiliacs infected through Cutter’s unheated concentrate, many dead.⁵
Canada: at least 2,000 HIV infections from blood products between 1980 and 1985, plus about 30,000 hepatitis C infections.⁹
United Kingdom: roughly 1,250 people with bleeding disorders infected with HIV, three-quarters of whom have died.¹⁰
Germany: about 1,800 hemophiliacs infected, some 400 dead by 1993.¹¹
France: at least 3,600 people infected through tainted transfusions, more than 1,000 dead.¹²

U.S. Lawsuits and Settlements

In the United States, thousands of hemophiliacs sued the four major manufacturers. A large group of claims was settled in 1997 as In re Factor VIII or IX Concentrate Blood Products Litigation.¹³²¹⁴ Individual verdicts were sometimes far larger: a Louisiana jury awarded $35.3 million in 1999 in K.D.D. Smith v. Alpha, though the award was later overturned on statute-of-limitations grounds and the case settled.

After the 2003 New York Times investigation drew from internal Cutter documents produced in the U.S. litigation, a class action was filed on behalf of thousands of foreign hemophiliacs against Bayer, Baxter, Armour, and Alpha Therapeutic.⁶ Plaintiffs alleged at least 5,000 hemophiliac infections in Europe, over 2,000 AIDS cases, and 1,250 deaths tied to the exported products.¹⁵

International Settlements

Japan (1995–1996). Bayer and Baxter subsidiaries agreed to pay 60% of a settlement worth up to $810 million, roughly $420,000 to $450,000 per HIV-infected victim, with the Japanese government covering the rest.¹⁶¹⁴

Taiwan (1998). Bayer and Baxter negotiated what they called “humanitarian aid,” paying $60,000 per claimant. The agreement included a “most-favored-nation” clause requiring the companies to match any higher compensation paid elsewhere. When Taiwanese claimants learned in 2003 that others had received more, they demanded Bayer honor the clause. Bayer refused, and the claimants sued in California. In 2009 a U.S. district court allowed the cases to proceed, finding California a more appropriate venue than Taiwan.¹³¹⁷

Canada. By 2006, over $1 billion in out-of-court settlements had been offered to Canadians infected between January 1986 and July 1990. The Canadian Red Cross pleaded guilty in 2005 to distributing contaminated blood and was fined $5,000.⁹

Germany (1995). Pharmaceutical firms contributed to a settlement package for victims.¹⁶

Criminal Prosecutions

Criminal accountability came harder than civil money, and outcomes varied sharply.

Japan

Prosecutors focused on Green Cross Corporation, an Osaka manufacturer that, like Cutter, kept selling unheated clotting products after safer alternatives existed. Three former Green Cross executives — President Renzo Matsushita, Vice President Tadakazu Suyama, and production chief Takehiko Kawano — pleaded guilty in 1997 to permitting the sale of HIV-tainted products. In February 2000 they received sentences ranging from 16 months to two years in prison, and Green Cross paid $216 million in compensation.⁸ Victims called the sentences grossly insufficient.

Two other figures were also charged. Dr. Takeshi Abe, a hemophilia expert who chaired the government’s AIDS study group, was arrested in August 1996 and accused of delaying approval of heat-treated products to favor Japanese firms.¹⁸ The Tokyo District Court acquitted him in 2001; an appeal was suspended in 2004 due to his dementia, and he died in 2005 at age 88. Akihito Matsumura, a former senior Health Ministry official, was convicted in 2001 of professional negligence for failing to halt the distribution and received a one-year suspended sentence.¹⁹

France

France’s contaminated blood affair produced the first trial of government ministers in the country since World War II. Former Prime Minister Laurent Fabius, former Social Affairs Minister Georgina Dufoix, and former Health Minister Edmond Hervé were tried before the Court of Justice of the Republic for manslaughter tied to the infection of seven people through 1985 transfusions.¹² In March 1999 Fabius and Dufoix were acquitted. Hervé was found guilty on two counts related to failing to expedite destruction of contaminated blood and failing to notify potential victims, but the court imposed no punishment, saying he had already suffered enough. Victims’ groups called the verdict “scandalous.” Earlier, around 1992, the head of France’s national blood transfusion service, Michel Garretta, had been sentenced to four years in prison for distributing contaminated products.²⁰

Germany

In Bayer’s home country, a scandal broke in 1993 when it emerged that a federal health agency had concealed suspicions about contaminated blood supplies dating back to 1985.²¹ The government disbanded the Federal Health Office and fired two senior officials. A German court convicted three executives of UB Plasma, a firm that had illegally pooled donations before HIV testing. Two former federal health ministers were also sued for failing to exercise proper oversight.¹¹

Canada

Canada’s Krever Commission, which issued its final report in November 1997, led to 32 criminal charges against senior figures at Health Canada, the Canadian Red Cross, and Armour Pharmaceutical.⁹ The Red Cross’s guilty plea and $5,000 fine in 2005 drew widespread criticism for its leniency.

Regulators and Public Inquiries

The FDA was widely criticized as slow. In March 1983 the agency sent letters to blood banks and manufacturers asking for donor screening and quarantine of products from donors with AIDS symptoms, but the letters did not require recall or destruction of existing stocks and their legal force was ambiguous.²² In July 1983 the FDA adopted a “case-by-case” recall policy rather than a blanket withdrawal of suspect lots.²³ The agency did not require the recall and destruction of all untreated clotting-factor units until 1989, six years after heat-treated alternatives became available. Even the FDA’s handling of Cutter’s overseas exports was passive: in May 1985, according to Cutter’s own records, FDA official Dr. Harry M. Meyer Jr. asked that the matter be “quietly solved without alerting the Congress, the medical community and the public.”³

Canada’s Krever Commission (1993–1997) heard from over 400 witnesses. Justice Horace Krever found that reliance on blood from high-risk donors, including U.S. prison populations, delays in heat treatment to save costs, and destruction of key documents by the Canadian Blood Committee all contributed to the catastrophe. The commission recommended no-fault compensation, which the government rejected, and the Red Cross was stripped of its blood program in favor of Canadian Blood Services and Héma-Québec.⁹

The United Kingdom’s Infected Blood Inquiry, chaired by Sir Brian Langstaff, published its final report on May 20, 2024 and officially concluded on March 31, 2026.²⁴ The inquiry found that pharmaceutical companies, including Bayer and Baxter subsidiaries, provided contaminated products that “should never have been licensed” and failed to give adequate warnings about HIV and hepatitis C risks.¹⁶ It found that patients were “falsely reassured” that blood products did not carry AIDS, and that research was conducted on patients, including children, without informed consent.¹⁰ The UK government accepted all 12 recommendations and set aside £11.8 billion for a compensation scheme run by the Infected Blood Compensation Authority.²⁵

Bayer’s Position

Through decades of litigation, Bayer maintained that it “always behaved responsibly, ethically, and humanely” in handling Factor VIII products.² Responding to the 2003 New York Times report, the company said its decisions had to be understood in the context of the science available in the 1980s and cited customer doubts about the efficacy of the heat-treated product and delays in international regulatory approvals.⁴

In 2024, in the context of the UK Infected Blood Inquiry, Bayer struck a different tone: “We are truly sorry that the haemophilia treatments developed by Cutter, intended to save and improve lives, ended up causing so much suffering.”¹⁶ A 2014 article in Accountability in Research called the episode an “overlooked” case of research misconduct and business ethics violations, arguing that Cutter had misrepresented its own findings, prioritized finances over patient safety, and targeted vulnerable populations in developing countries.²⁶

1
National Academies Press. HIV and the Blood Supply: An Analysis of Crisis Decisionmaking
2
The Guardian. Bayer Division Sold HIV-Risky Drug
3
Infected Blood Inquiry. 2 Paths of Bayer Drug in 80s: Riskier One Steered Overseas
4
CBS News. Bayer Sold HIV-Risky Meds
5
The New York Times. 2 Paths of Bayer Drug in 80s: Riskier One Steered Overseas
6
CBC. Bayer Hit With Bad Blood Lawsuit
7
Hemophilia Federation of America. Questions and Answers
8
CBS News. Japan Convictions in Blood Scandal
9
The Canadian Encyclopedia. Krever Inquiry
10
Infected Blood Inquiry. Infected Blood Inquiry Final Report, Volume 1
11
Los Angeles Times. Blood-Contamination Scandal Grows in Germany
12
CBS News. Guilty Verdict in Blood Scandal
13
Wisner Baum LLP. Background: Plaintiffs Position
14
Infected Blood Inquiry. Contaminated Blood International Compensation Schemes
15
PubMed Central. HIV-Contaminated Blood Products
16
The Guardian. Infected Blood Scandal: Call for Drug Firms to Pay Part of £10bn Compensation
17
Law360. Taiwan HIV Hemophiliac Cases Head Back to Calif
18
The New York Times. Japan Arrests Doctor in Case of Bad Blood
19
The Japan Times. Abe, Central Figure in HIV-Tainted Blood Products Scandal, Dies
20
The Guardian. Blood Trial Acquittals Spark Fury
21
The Washington Post. HIV-Infected Blood Scandal Rocks German Health Program
22
National Center for Biotechnology Information. HIV and the Blood Supply – The Response of the Blood Banking Industry
23
National Center for Biotechnology Information. HIV and the Blood Supply – Decisions Made by Government
24
UK House of Commons Library. Infected Blood Inquiry
25
UK Government. Final Government Response to the Infected Blood Inquiry
26
PubMed. Blood Money: Bayers Inventory of HIV-Contaminated Blood Products and Third World Hemophiliacs